Plain-English translation of NCT07303894 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether —a natural compound derived from plants—can reduce markers in your blood that signal an increased risk of blood clots in people with ovarian cancer. Blood clots are a known side effect concern for cancer patients receiving chemotherapy. The study will compare the medication to a placebo (a pill with no active ingredient) to see if it actually works.
People with ovarian cancer receiving chemotherapy have a higher-than-normal risk of developing dangerous blood clots. Researchers want to know if this medication can lower that risk by changing how blood clotting proteins work in your body.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive either a placebo or the medication once or twice daily by mouth. Your participation would start on the first day of your chemotherapy and continue alongside your cancer treatment. You'll have blood tests at regular intervals to measure clotting markers and check your overall health. The study team will monitor you closely for any side effects or bleeding concerns throughout your involvement.
AI-generated summary from trial data · Aug 8, 2026 · Not medical advice
United States